Cochrane · systematic review · CD007923
Timing of dornase alfa inhalation for cystic fibrosis
Dentice, R, Elkins, M · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
9
No studies
1
Included studies
NR
No studies 1 · 10%Ungraded 0 · 0%Very low 3 · 30%Low 6 · 60%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyInhalation of dornase alfa before versus after airway clearance techniques
Population: adults and children with cystic fibrosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
FEV1 (% predicted) change from baseline Inhalation of dornase alfa before vs after airway clearance techniques | MD 0.83 | 102 participants | Very low Downgraded: risk of bias, indirectness |
FVC (% predicted) change from baseline Inhalation of dornase alfa before vs after airway clearance techniques | MD 1.06 | 77 participants | Low Downgraded: risk of bias, indirectness |
Measures of QoL and symptom scores Inhalation of dornase alfa before vs after airway clearance techniques | no estimate extracted | 102 participants | Very low Downgraded: risk of bias, indirectness |
FEF25-75 (% predicted) Inhalation of dornase alfa before vs after airway clearance techniques | no estimate extracted | 25 participants | Low Downgraded: risk of bias, indirectness |
Adverse effects Inhalation of dornase alfa before vs after airway clearance techniques | no estimate extracted | 102 participants | Very low Downgraded: risk of bias, indirectness |
Morning versus evening inhalation of dornase alfa
Population: adults and children with cystic fibrosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
FEV1 (% predicted) change from baseline Morning vs evening inhalation of dornase alfa | no estimate extracted | 25 participants | Low Downgraded: risk of bias, indirectness |
FVC (% predicted) change from baseline Morning vs evening inhalation of dornase alfa | no estimate extracted | 25 participants | Low Downgraded: risk of bias, indirectness |
Measures of QoL and symptom scores Morning vs evening inhalation of dornase alfa | no estimate extracted | 25 participants | Low Downgraded: risk of bias, indirectness |
FEF25-75 (% predicted) Morning vs evening inhalation of dornase alfa | no estimate extracted | NR | No studies |
Adverse effects Morning vs evening inhalation of dornase alfa | no estimate extracted | 25 participants | Low Downgraded: risk of bias, indirectness |
Inhalation of dornase alfa before versus after airway clearance techniques
Population: adults and children with cystic fibrosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
FEV1 (% predicted) change from baseline Inhalation of dornase alfa before vs after airway clearance techniques | MD 0.83 | 102 participants | Very low Downgraded: risk of bias, indirectness |
FVC (% predicted) change from baseline Inhalation of dornase alfa before vs after airway clearance techniques | MD 1.06 | 77 participants | Low Downgraded: risk of bias, indirectness |
Measures of QoL and symptom scores Inhalation of dornase alfa before vs after airway clearance techniques | no estimate extracted | 102 participants | Very low Downgraded: risk of bias, indirectness |
FEF25‐75 (% predicted) Inhalation of dornase alfa before vs after airway clearance techniques | no estimate extracted | 25 participants | Low Downgraded: risk of bias, indirectness |
Adverse effects Inhalation of dornase alfa before vs after airway clearance techniques | no estimate extracted | 102 participants | Very low Downgraded: risk of bias, indirectness |
Morning versus evening inhalation of dornase alfa
Population: adults and children with cystic fibrosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
FEV1 (% predicted) change from baseline Morning vs evening inhalation of dornase alfa | no estimate extracted | 25 participants | Low Downgraded: risk of bias, indirectness |
FVC (% predicted) change from baseline Morning vs evening inhalation of dornase alfa | no estimate extracted | 25 participants | Low Downgraded: risk of bias, indirectness |
Measures of QoL and symptom scores Morning vs evening inhalation of dornase alfa | no estimate extracted | 25 participants | Low Downgraded: risk of bias, indirectness |
FEF25‐75 (% predicted) Morning vs evening inhalation of dornase alfa | no estimate extracted | NR | No studies |
Adverse effects Morning vs evening inhalation of dornase alfa | no estimate extracted | 25 participants | Low Downgraded: risk of bias, indirectness |